Hypnosis to Manage Pain and Symptoms in Patients With Sickle Cell Disease

NCT00393250 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 31

Last updated 2021-10-29

No results posted yet for this study

Summary

This study will examine whether hypnosis can reduce the frequency and intensity of pain in patients with sickle cell disease.

Patients 18 years of age and older with sickle cell disease and a history of pain associated with their disease may be eligible for this study.

Participants are interviewed to assess their frequency and intensity of pain, sleep quality, coping strategies, mood and anxiety and are then randomly assigned to study Group A or B (see below). All participants are given pain diaries to complete at home and turn in at each clinic visit. They undergo the following procedures:

Group A

Weeks 1-4: Receive weekly 60-minute hypnosis sessions, in which they are given suggestions for relieving pain, reducing anxiety, improving sleep and enhancing their health and well-being. The sessions are audio- and videotaped.

Week 5: Are interviewed to assess pain, sleep, coping strategies, mood and anxiety.

Week 6: Receive a DVD player and DVD with instruction on how to perform self-hypnosis. They practice hypnosis at home as often as needed, but at least once a day. They record in a pain diary in the morning and the evening their amount of pain, medication use, school or work attendance, quality and amount of sleep and number of times they use self-hypnosis.

Weeks 8, 10 and 12: Turn in their pain diaries and have a pain assessment.

Week 12: Are assessed for how they respond to the hypnosis.

Group B

Weeks 1-4: Receive weekly 60-minute sessions of education about sickle cell disease.

Week 5: Are interviewed to assess pain, sleep, coping strategies, mood and anxiety.

Week 6: Turn in their daily pain diaries and receive a DVD player and DVD that contains educational materials about sickle cell disease.

Weeks 8, 10 and 12: Turn in their pain diaries and have a pain assessment.

Weeks 13-24: Follow the procedures described in weeks 1-12 for Group A.

Conditions

Interventions

OTHER

Hypnosis

Subjects receive hypnosis (experimental intervention) during 4 weeks of face-to-face encounters with a physician trained in hypnosis. For 6 weeks following the instruction period, the participants will perform daily self- hypnosis using customizable digital media.

OTHER

Control

Subjects in the control arm of the study will receive face-to-face education regarding sickle cell disease for the same length and frequency as the treatment group hypnosis encounters before crossing over to the experimental intervention arm of the study

Sponsors & Collaborators

  • National Institutes of Health Clinical Center (CC)

    lead NIH

Principal Investigators

  • Gwenyth R Wallen, Ph.D. · National Institutes of Health Clinical Center (CC)

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-04-30
Primary Completion
2012-06-04
Completion
2012-06-04

Countries

  • United States

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00393250 on ClinicalTrials.gov